| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | 
|---|---|---|---|---|---|---|
Income Statement  | ||||||
| Total Revenue | 77.14M | 75.51M | 83.14M | 52.52M | 113.97M | 99.48M | 
| Gross Profit | 22.11M | 20.74M | 14.68M | 10.83M | 41.73M | 38.58M | 
| EBITDA | -65.72M | -74.79M | -4.51M | -61.82M | -29.28M | -25.02M | 
| Net Income | -40.38M | -47.43M | -7.29M | -67.91M | -40.61M | -78.33M | 
Balance Sheet  | ||||||
| Total Assets | 2.95B | 3.20B | 1.83B | 1.98B | 2.77B | 2.84B | 
| Cash, Cash Equivalents and Short-Term Investments | 84.52M | 152.56M | 263.55M | 164.96M | 318.68M | 150.76M | 
| Total Debt | 110.93M | 90.49M | 115.50M | 141.74M | 178.95M | 497.97M | 
| Total Liabilities | 454.60M | 474.25M | 334.40M | 362.69M | 545.67M | 904.76M | 
| Stockholders Equity | 2.49B | 2.73B | 1.49B | 1.62B | 2.22B | 1.94B | 
Cash Flow  | ||||||
| Free Cash Flow | -86.81M | -94.51M | -52.68M | -92.82M | 82.82M | -10.62M | 
| Operating Cash Flow | -71.22M | -80.87M | -43.59M | -77.91M | 105.22M | 3.40M | 
| Investing Cash Flow | 167.01M | 162.66M | 43.10M | -104.25M | 369.21M | -64.92M | 
| Financing Cash Flow | 4.12M | -21.65M | -22.38M | -23.79M | -325.97M | -42.38M | 
Name  | Overall Rating  | Market Cap  | P/E Ratio  | ROE  | Dividend Yield  | Revenue Growth  | EPS Growth  | 
|---|---|---|---|---|---|---|---|
| ― | HK$876.00M | 1.74 | 12.24% | ― | 13.37% | 15.55% | |
| ― | HK$950.47M | 3.65 | 8.32% | 4.18% | 8.09% | 30.76% | |
| ― | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
| ― | HK$1.25B | 10.98 | 3.91% | 3.73% | 20.53% | 28.42% | |
| ― | HK$718.56M | -2.15 | -89.45% | ― | 12.16% | -16700.00% | |
| ― | HK$646.36M | -2.64 | -98.45% | ― | -32.75% | 38.59% | |
| ― | HK$905.07M | ― | -1.99% | ― | -5.59% | -1071.43% | 
KuangChi Science Limited has proposed to change its English name to Genesis Scale Holdings Limited and adopt a new Chinese name. This change aims to provide a fresh corporate image that supports future business development. The name change is subject to shareholder approval and regulatory consent in Bermuda. The change will not affect shareholder rights, and existing share certificates will remain valid.
The most recent analyst rating on (HK:0439) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on KuangChi Science Limited stock, see the HK:0439 Stock Forecast page.
KuangChi Science Limited has announced the expiration of its 2012 Share Option Scheme, which was adopted on July 31, 2012, and expired on July 30, 2022. In response, the company proposes to adopt a New Share Option Scheme to provide incentives for participants contributing to the company’s growth. This proposal is subject to shareholder approval and the necessary permissions from the Stock Exchange. The new scheme aims to continue motivating and rewarding participants, aligning with the company’s strategic goals.
The most recent analyst rating on (HK:0439) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on KuangChi Science Limited stock, see the HK:0439 Stock Forecast page.
KuangChi Science Limited has announced a change in its executive directors, with Dr. Liu Ruopeng, Dr. Luan Lin, and Dr. Ji Chunlin resigning to focus on other business commitments. The company has appointed Dr. Liu Weiwen, the current CEO, and Mr. Lin Ge as new executive directors, effective from September 10, 2025. This leadership change is part of the company’s ongoing management restructuring, which may impact its strategic direction and operational focus.
KuangChi Science Limited has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The company has also detailed the membership of its board committees, which are the Audit Committee, Nomination Committee, and Remuneration Committee. This announcement provides clarity on the leadership structure and governance of KuangChi Science Limited, potentially impacting its strategic direction and stakeholder engagement.
KuangChi Science Limited reported its unaudited interim results for the six months ending June 30, 2025, showing a revenue increase to HK$33,656,000 from HK$32,028,000 in the same period of 2024. Despite a rise in gross profit, the company faced an operating loss of HK$4,504,000, although it achieved a net profit of HK$1,821,000, marking a significant turnaround from a loss in the previous year.